By Connor Hart
Shares of Arvinas fell after the company said its in-development treatment for breast cancer didn't reach statistical significance in improving progression-free survival for its intent-to-treat population.
The stock declined 9.7%, to $6.50, in pre-market trading Monday. Shares ended Friday's regular session 4% lower, at $7.20, having lost about three-quarters of their value in the past year.
The biotechnology said that the therapy, vepdegestrant, notched a progression-free survival rate of 3.7 months in a recent Phase 3 study, compared with a progression-free survival rate of 3.6 months for fulvestrant, an existing breast cancer treatment.
Arvinas noted that vepdegestrant, which is being developed alongside Pfizer to treat certain types of advanced or metastatic breast cancer, was generally well tolerated in the clinical trial, and that the therapy did demonstrate a meaningful improvement in progression-free survival among estrogen receptor 1 mutation patients.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
June 02, 2025 07:16 ET (11:16 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。